Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare executive reports planned stock sale. EVP of Corporate Affairs Joseph S. Konowiecki sold 25,000 shares of Alignment Healthcare, Inc. common stock in an open-market transaction at $22.00 per share. Following this sale, he directly holds 1,153,816 shares. A footnote states the transaction was carried out under a Rule 10b5-1 trading plan adopted on 03/04/2026, indicating the sale was pre-arranged rather than timed discretionarily.
ALHC reports a Form 144 notice for a proposed sale of 25,000 common shares by Joseph Konowiecki.
The filing lists the proposed sale date as 06/11/2026 and an aggregate sale value of $525,000. It also shows a stock bonus of 75,000 shares vested on 10/06/2014 and lists 550,000 shares outstanding as of 06/18/2026.
Alignment Healthcare, Inc. president Dawn Christine Maroney reported an open-market sale of 30,000 shares of common stock at a weighted-average price of $19.5475 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on May 22, 2025. After this sale, she directly holds 947,313 shares, indicating a large remaining ownership position.
Alignment Healthcare, Inc. Chief Medical Officer Hyong Kim reported an open-market sale of common stock. On June 12, 2026, Kim sold 35,951 shares at a weighted-average price of $19.8589 per share under a pre-arranged Rule 10b5-1 plan adopted on March 13, 2026.
After this transaction, Kim directly holds 331,750 shares of Alignment Healthcare common stock. The filing shows a single net-sell transaction with no derivative exercises or gifts disclosed in this report.
ALHC filed a Form 144 notice indicating proposed sales of Common stock consisting of 35,951 shares tied to restricted stock units granted 03/13/2026. The filing lists a prior sale by Hyong J Kim of 18,404 shares on 03/18/2026 for $328,327.36.
The filing is a regulatory notice of intended resale by an issuer/holder under applicable resale rules; timing and distribution mechanics are included in the filing headings.
Morgan Stanley Smith Barney LLC reports a Form 144 filing indicating securities sold by Sebastian Burzacchi. The filing lists a sale of 15,361 common shares on 03/18/2026 for $274,040.24. It also shows 1,142 Restricted Stock Units dated 03/13/2026 and the filing appears on 06/12/2026.
Alignment Healthcare, Inc. executive Joseph S. Konowiecki, EVP of Corporate Affairs and a director, reported an open-market sale of company stock. On June 11, 2026, he sold 25,000 shares of Common Stock at $21.00 per share in a non-derivative transaction.
After this sale, he directly holds 1,178,816 shares of Alignment Healthcare common stock. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating it was scheduled in advance rather than timed opportunistically.
Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported indirect open-market sales of company common stock made through the JEK Trust, of which he is trustee. On June 10, 2026, the trust sold 223,064 shares at a weighted-average price of $20.5962 per share and 74,936 shares at a weighted-average price of $19.6481 per share, under a Rule 10b5-1 trading plan adopted on November 21, 2025. Following these transactions, the JEK Trust held 1,609,830 shares indirectly, while Mr. Kao’s direct holdings were 1,608,743 shares, after a transfer of 176,125 shares from direct ownership to the trust.
Alignment Healthcare, Inc. reported the results of its virtual annual stockholder meeting held on June 4, 2026. Stockholders representing 194,112,992 shares of common stock were present or represented by proxy.
All three Class II director nominees — Jody Bilney, David Hodgson, and Jacqueline Kosecoff — were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on an advisory basis, stockholders approved the compensation of the company’s named executive officers in the say-on-pay vote.